Anika Therapeutics (ANIK) Return on Capital Employed (2011 - 2026)
Anika Therapeutics (ANIK) posted quarterly Return on Capital Employed of 3.22% for Q2 2026, up 213.0% year-over-year from 1.03% in Q2 2025, and up 57.01% quarter-over-quarter from 7.48% in Q1 2026.
Anika Therapeutics (ANIK) Return on Capital Employed (2011 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has reported Return on Capital Employed for 16 consecutive years, with 3.22% the latest figure, recorded in Q2 2026.
- In Q2 2026, Return on Capital Employed rose 213.0% year-over-year to 3.22%; the TTM figure through Jun 2026 stood at 3.22% (up 213.0% YoY), while the FY2025 annual figure was 6.33%, down 394.0% from the prior year.
- Return on Capital Employed improved to 3.22% in Q2 2026 per ANIK's latest filing, from 7.48% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 9.17% in Q3 2024 and bottomed at 7.48% in Q1 2026.
- Historically, Return on Capital Employed has averaged 1.88% across 5 years, with a median of 2.56% in 2024.
- Annual changes were most pronounced in 2024 — Return on Capital Employed jumped 1165 bps — and 2025, when it plunged 1648 bps.
- Anika Therapeutics' Return on Capital Employed stood at 1.15% in 2022, then sank by 73 bps to 0.31% in 2023, then plunged by 937 bps to 2.63% in 2024, then plunged by 150 bps to 6.58% in 2025, then soared by 51 bps to 3.22% in 2026.
- Business Quant data shows ANIK's Return on Capital Employed at 3.22% in Q2 2026, 7.48% in Q1 2026, and 6.58% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Anika Therapeutics | 285.40 Mn | 246.98 Mn | 21.24 Mn | -3.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.22% |
| Mar 31, 2026 | -7.48% |
| Dec 31, 2025 | -6.58% |
| Sep 30, 2025 | -7.32% |
| Jun 30, 2025 | -5.34% |
| Mar 31, 2025 | -3.85% |
| Dec 31, 2024 | -2.63% |
| Sep 30, 2024 | 9.17% |
| Jun 30, 2024 | 5.36% |
| Mar 31, 2024 | 4.56% |
| Dec 31, 2023 | 0.31% |
| Sep 30, 2023 | -2.48% |
| Jun 30, 2023 | -1.80% |
| Mar 31, 2023 | -1.69% |
| Dec 31, 2022 | 1.15% |
| Sep 30, 2022 | -6.73% |
| Jun 30, 2022 | -4.63% |
| Mar 31, 2022 | -0.69% |
| Dec 31, 2021 | 0.82% |
| Sep 30, 2021 | -1.89% |